ArticleBMC cancer2025
Pancreatic cancer in China: the analysis of cancer mortality and burden in China, 2008-2021.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo understand the baseline characteristics and changing trends of pancreatic cancer mortality and disease burden, we statistically analyze the mortality data among Chinese residents from 2008 to 2021.
methodsPancreatic cancer mortality data were selected from China Cause of Death Surveillance Dataset. We calculated Crude Mortality Rate (CMR), age-standardized mortality rate (ASMR), potential years of life lost (PYLL), and PYLL rate (PYLLR) stratified by sex, age, urban/rural residence, and region (eastern/central/western China). The average annual percentage change (AAPC) was used to quantify trends in ASMR and PYLLR. Chi-square tests (R4.4.3) assessed mortality differences across subgroups, while an age-period-cohort (APC) model analyzed the effects of age, period, and birth cohort on mortality trends.
resultsThe ASMR of pancreatic cancer in China increased from 3.67/100,000 in 2008 to 4.45/100,000 in 2021 (AAPC = 1.09%), while PYLLR rose from 0.23% to 0.35% (AAPC = 3.13%). Subgroup disparities: Both ASMR and PYLLR were higher in males than females, urban than rural areas, and eastern > central > western regions. Burden acceleration: The fastest increases occurred in males (vs. females), rural (vs. urban), and western > central > eastern regions.
conclusionPancreatic cancer mortality and disease burden in China show a sustained upward trend, disproportionately affecting older adults, males, urban residents, and eastern populations. Rapid escalation in males, rural areas, and western regions underscores the need for targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.